These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 17140572

  • 1. The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol.
    Fatemi HM, Camus M, Kolibianakis EM, Tournaye H, Papanikolaou EG, Donoso P, Devroey P.
    Fertil Steril; 2007 Mar; 87(3):504-8. PubMed ID: 17140572
    [Abstract] [Full Text] [Related]

  • 2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 3. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P.
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [Abstract] [Full Text] [Related]

  • 4. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, Thomsen L, Humaidan P.
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [Abstract] [Full Text] [Related]

  • 5. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial.
    Fatemi HM, Kolibianakis EM, Camus M, Tournaye H, Donoso P, Papanikolaou E, Devroey P.
    Hum Reprod; 2006 Oct; 21(10):2628-32. PubMed ID: 16857887
    [Abstract] [Full Text] [Related]

  • 6. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G, Crosignani PG.
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [Abstract] [Full Text] [Related]

  • 7. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
    Pirard C, Donnez J, Loumaye E.
    Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
    [Abstract] [Full Text] [Related]

  • 8. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
    Gizzo S, Andrisani A, Esposito F, Noventa M, Di Gangi S, Angioni S, Litta P, Gangemi M, Nardelli GB.
    Gynecol Endocrinol; 2014 Jul; 30(12):902-8. PubMed ID: 25268567
    [Abstract] [Full Text] [Related]

  • 9. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, Hornung D, Diedrich K, Felberbaum R.
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [Abstract] [Full Text] [Related]

  • 10. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
    Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J.
    Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT, Ohlinger R.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):87-92. PubMed ID: 16377065
    [Abstract] [Full Text] [Related]

  • 12. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist.
    Tavaniotou A, Albano C, Smitz J, Devroey P.
    Fertil Steril; 2002 Apr 01; 77(4):733-7. PubMed ID: 11937125
    [Abstract] [Full Text] [Related]

  • 13. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN, Phung HT, Ho MT.
    Hum Reprod; 2015 May 01; 30(5):1188-95. PubMed ID: 25740882
    [Abstract] [Full Text] [Related]

  • 14. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists.
    Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P.
    Fertil Steril; 2004 Jul 01; 82(1):102-7. PubMed ID: 15236997
    [Abstract] [Full Text] [Related]

  • 15. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM, Bates GW, Robinson RD, Arthur NJ, Martin JE, Neal GS.
    Fertil Steril; 2006 Jul 01; 86(1):58-63. PubMed ID: 16753156
    [Abstract] [Full Text] [Related]

  • 16. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C.
    Fertil Steril; 2010 Feb 01; 93(3):847-54. PubMed ID: 19200959
    [Abstract] [Full Text] [Related]

  • 17. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix.
    de Jong D, Macklon NS, Fauser BC.
    Fertil Steril; 2000 May 01; 73(5):1051-4. PubMed ID: 10785238
    [Abstract] [Full Text] [Related]

  • 18. Determinants of the hCG Concentration in the Early Luteal Phase After Final Maturation of Follicles With Bolus Trigger of Recombinant hCG.
    Vuong LN, Pham TD, Ho VNA, Ho TM, Humaidan P, Andersen CY.
    Front Endocrinol (Lausanne); 2020 May 01; 11():137. PubMed ID: 32265836
    [Abstract] [Full Text] [Related]

  • 19. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG, Bourgain C, Kolibianakis E, Tournaye H, Devroey P.
    Hum Reprod; 2005 Jun 01; 20(6):1541-7. PubMed ID: 15705618
    [Abstract] [Full Text] [Related]

  • 20. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L, Tournaye H, Stoop D, Van Vaerenbergh I, Bourgain C, Polyzos NP, Haentjens P, Blockeel C.
    Reprod Biomed Online; 2014 Mar 01; 28(3):359-68. PubMed ID: 24456700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.